Created at	Source	Raw Value	Validated value
June 7, 2022, 3:30 p.m.	usa	Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Measurements;Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters;Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interests (AESIs), TEAEs Leading to Treatment Discontinuation and Serious TEAEs (SAEs) According to NCI-CTCAE Version 5.0;Time to Recovery	Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Measurements;Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters;Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interests (AESIs), TEAEs Leading to Treatment Discontinuation and Serious TEAEs (SAEs) According to NCI-CTCAE Version 5.0;Time to Recovery
April 6, 2021, 12:31 a.m.	usa	Number of Participants With Clinically Significant Changes in Laboratory Parameters and Electrocardiogram Findings;Occurrence of Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interests (AESIs), TEAEs Leading to Treatment Discontinuation and Serious AEs (SAEs);Time to Recovery	Number of Participants With Clinically Significant Changes in Laboratory Parameters and Electrocardiogram Findings;Occurrence of Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interests (AESIs), TEAEs Leading to Treatment Discontinuation and Serious AEs (SAEs);Time to Recovery
Oct. 26, 2020, 11:31 p.m.	usa	Percentage of Participants Alive and not Requiring Supplemental Oxygenation;Number of Participants With Clinically Significant Changes in Laboratory Parameters and Electrocardiogram Findings;Occurrence of Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interests (AESIs), TEAEs Leading to Treatment Discontinuation and Serious AEs (SAEs)	Percentage of Participants Alive and not Requiring Supplemental Oxygenation;Number of Participants With Clinically Significant Changes in Laboratory Parameters and Electrocardiogram Findings;Occurrence of Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interests (AESIs), TEAEs Leading to Treatment Discontinuation and Serious AEs (SAEs)